Sanofi Scores FDA Approval For Flu-Shot Facility In US


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • The FDA has approved Sanofi SA's (NASDAQ:SNY) newly completed plant in Swiftwater, Pennsylvania.
  • The license will allow Sanofi to begin production of its Fluzone High-Dose vaccine for the 2021-22 flu season.
  • With $425 million of investment, the opening of the new plant will require Sanofi to add up to 200 employees.
  • Fluzone High-Dose is a quadrivalent vaccine targeting four flu strains.
  • Price Action: SNY shares are down 0.43% at $53.19 during the market trading session on the last check Thursday.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsHealth CareFDAGeneralBriefs